Suven Life Sciences Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), more than Two Months Ahead of Schedule".
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences has completed full patient enrollment for the Phase-2b clinical trial of its drug candidate Ropanicant, being tested for Major Depressive Disorder (MDD). The company reached this milestone more than two months ahead of its planned schedule. Phase-2b is a mid-stage trial that tests how effective the drug is at the right dose. Faster enrollment does not change the trial timeline for results but reduces execution risk. No financial or revenue details were disclosed in the press release.
Positive sentiment for the stock as faster enrollment signals operational efficiency and preserves R&D momentum, but no immediate financial impact — actual value depends on upcoming trial results and any future regulatory approval, which is still years away.